Comment from National Consumers League
AnonymousSupportAdvocacy
Summary: The National Consumers League supports the FDA's proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. They argue that mass compounding of these GLP-1 drugs poses significant safety risks, lacks clinical need, and is being exploited by deceptive marketing practices.
Attached are comments from the National Consumers League in support of FDA's proposed rule FDA-2018-N-3240.